SEC Tracker
Get the app

Inovio Pharmaceuticals INO

Inovio Pharmaceuticals gets FDA approval for VOCERYQ

Item 7.01 Investor disclosure, Item 8.01 Other events

Form
8-K
Filed
Importance
Notable
  1. FDA granted accelerated approval for VOCERYQ to reduce surgery frequency in RRP patients.
  2. Confirmatory study required for continued approval, with draft protocol due by end of 2026.
  3. VOCERYQ expected to be available in 60 days, full deployment in Q1 2027.

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Inovio Pharmaceuticals files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Macrogenics MGNX public float $74M, Jun 30, 2025
  2. Volitionrx VNRX public float $73M, Jun 30, 2025
  3. Gyre Therapeutics GYRE public float $73M, Jun 30, 2025
  4. Oncolytics Biotech ONCY public float $72M, Jun 30, 2025
  5. Seres Therapeutics MCRB public float $72M, Jun 30, 2025